RxDoctor Payments Data

Steven Sherman, MD

Internal Medicine · Wellington, FLNPI 1003998345

Payments from drug & device makers

$606in general payments, 2019–2025

Across 33 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$108
  • Otsuka America Pharmaceutical, Inc.$83
  • AbbVie$60
  • Lilly USA, LLC$58
  • Novo Nordisk$56
  • Exact Sciences$45
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$606 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$552,439
Medicare patients
981
Services billed
6,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban797$277,196
XareltoRivaroxaban139$44,938
JardianceEmpagliflozin72$35,434
EntrestoSacubitril/Valsartan122$34,987
JanuviaSitagliptin Phosphate78$29,210
TrulicityDulaglutide22$14,173
Atorvastatin Calcium758$13,636
Vancomycin Hcl42$13,086
SantylCollagenase Clostridium Hist.37$12,932
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog77$12,853
Daptomycin11$12,071
MultaqDronedarone Hcl24$11,357
LinzessLinaclotide19$10,522
RestasisCyclosporine26$10,459
MyrbetriqMirabegron37$9,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$42$44,938139 claims
AbbVieLinzess, Restasis, Restasis Multidose$60$30,08357 claims
Lilly USA, LLCTrulicity$58$14,17322 claims
GSKTrelegy Ellipta, Arexvy$19$13,36030 claims
Astellas Pharma US IncMyrbetriq$108$9,59837 claims
Otsuka America Pharmaceutical, Inc.Rexulti$83$5,71512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →